Liquid Biopsy in Solid Malignancy
GENETIC TESTING AND MOLECULAR BIOMARKERS, vol.23, no.4, pp.284-296, 2019 (SCI-Expanded, Scopus)
- Publication Type: Article / Article
- Volume: 23 Issue: 4
- Publication Date: 2019
- Doi Number: 10.1089/gtmb.2018.0237
- Journal Name: GENETIC TESTING AND MOLECULAR BIOMARKERS
- Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
- Page Numbers: pp.284-296
- Hacettepe University Affiliated: No
Abstract
The clinical utility of tissue biopsies in cancer management will continue to expand, especially with the evolving role of targeted therapies. "Liquid biopsy" refers to testing a patient's biofluid samples such as blood or urine to detect tumor-derived molecules and cells that can be used diagnostically and prognostically in the assessment of cancer. Many proof-of-concept and pilot studies have shown the clinical potential of liquid biopsies as diagnostic and prognostic markers which would provide a surrogate for the conventional "solid biopsy". In this review, we focus on three methods of liquid biopsy-circulating tumor cells, extracellular vesicles, and circulating tumor DNA-to provide a landscape view of their clinical applicability in cancer management and research.